ProFactor Pharma LTD
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News
Select Page

Seed Financing

by Richard Cruse | Aug 20, 2013 | News

ProFactor Pharma closed its round of financing in August 2013. The funding was provided principally by members of the Business Angel Syndicate Kelvin Capital, Glasgow, and the Scottish Investment Bank Co-investment Fund. Some of the existing shareholders, including...
Next Entries »

Articles

  • ProFactor Pharma Ltd. secures funding to develop a novel enhanced half-life recombinant human Factor VIII February 6, 2025
  • World Hemophilia Day April 11, 2024
  • Eugenia Wachters appointed Chief Operating Officer at ProFactor Pharma July 10, 2023
  • World Hemophilia Day April 19, 2023
  • ProFactor Pharma (PFP) realise further capital injection – August 2022 September 20, 2022
  • Health Tech World – Interview – Ending the Haemophilia Drug Shortage (23 November 2021) November 24, 2021
  • Profactor Pharma Announces Issuance of Indian and Eurasian Patent Covering a high yielding cell line for treatment of Haemophilia A March 31, 2021
  • Profactor Pharma completes optimisation of process for manufacture of lowest cost recombinant FVIII January 31, 2021
  • World-wide inequalities in Haemophilia care. Things are getting better? January 19, 2021
  • Outstanding technical progress July 15, 2020
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News